Barely Significant
← all excerpts

First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study.

Breast · 2021 · PMC8053791 · PMID 33812267

Europe PMCDOI
1
hedged sentence
0.0800
closest p · 1.6× alpha
0.0800
boldest claim

The sentences

showed a trendp = 0.08so close (0.05 < p ≤ 0.1)
PPS Univariate analysis for PPS1, showed a trend for better PPS in women treated with first-line ET as compared to ET plus CDK4/6i (HR: 0.63, C·I.: 0.37–1.06, p = 0.08) ( Figure S4 ). 3.2.4.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.